A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT05357690

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
  • Mayo Clinic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05357690
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05357690. Randomized; quadruple masking; primary purpose prevention. Start 2023-04-19 (actual); primary completion 2026-06-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
Intervention (Procedure)
Stellate ganglion block
Intervention (Drug)
Bupivacaine
Intervention (Drug)
Placebo
Lead sponsor
Mayo Clinic (class: other)

Record details

Record id
cardio:ct-nct05357690
Content hash
75e1a86f04a413fc39f958bb919a99590e30340cca06494d16f5b4cbdf9547ad